Canada markets closed

Sutro Biopharma, Inc. (S09.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
3.4200-0.0600 (-1.72%)
At close: 03:29PM CEST

Sutro Biopharma, Inc.

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 881 6500

Full Time Employees302

Key Executives

NameTitlePayExercisedYear Born
Mr. William J. Newell J.D.CEO & Director1.01MN/A1958
Ms. Jane Chung R.Ph.President & COO876.97kN/A1972
Dr. James R. Swartz DSc, Ph.D., Sc.D.FounderN/AN/AN/A
Mr. Edward C. Albini M.B.ACFO & Secretary559.6kN/A1958
Dr. Venkatesh Srinivasan Ph.d.Chief Technical Operations OfficerN/AN/AN/A
Dr. Hans-Peter Gerber Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. David Pauling J.D., M.A.General CounselN/AN/AN/A
Ms. Linda A. FitzpatrickChief People & Communications Officer559.03kN/A1957
Dr. Nicki Vasquez Ph.D.Chief Portfolio Strategy & Alliance OfficerN/AN/A1963
Dr. Anne Elizabeth Borgman-Hagey M.D.Chief Medical OfficerN/AN/A1969
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Corporate Governance

Sutro Biopharma, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.